ELI LILLY AND COMPANY Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, before Tax
ELI LILLY AND COMPANY (LLY) reported Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, before Tax of -$6.00 million for the 12-month period ending 2018-12-31, per its 10-K filed 2021-02-17.
Discontinued › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesBeforeTax · last filed 2021-02-17
- ELI LILLY AND COMPANY other comprehensive income (loss), derivatives qualifying as hedges, before tax for fiscal 2018 was -$6.00M, a 121.58% decline from fiscal 2017.
- ELI LILLY AND COMPANY other comprehensive income (loss), derivatives qualifying as hedges, before tax for fiscal 2017 was $27.80M.
- ELI LILLY AND COMPANY other comprehensive income (loss), derivatives qualifying as hedges, before tax for fiscal 2015 was -$42.00M.
- ELI LILLY AND COMPANY other comprehensive income (loss), derivatives qualifying as hedges, before tax for fiscal 2014 was -$14.50M.
| Period end | Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, before Tax 12 month |
|---|---|
| 2018-12-31 | -$6.00M 10-K · filed 2021-02-17 |
| 2017-12-31 | $27.80M 10-K · filed 2020-02-19 |
| 2016-12-31 | $11.70M 8-K · filed 2019-10-24 |
| 2015-12-31 | -$42.00M 10-K · filed 2018-02-20 |
| 2014-12-31 | -$14.50M 10-K · filed 2017-02-21 |
| 2013-12-31 | -$123.80M 10-K · filed 2016-02-19 |
| 2012-12-31 | $8.70M 10-K · filed 2015-02-19 |
| 2011-12-31 | $44.80M 10-K · filed 2014-02-19 |
| 2010-12-31 | -$26.60M 10-K · filed 2013-02-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Akari Therapeutics Plc (AKTX) | $1,527.991B | -47,921.42 | |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |